Drug Profile
AVE 0897
Alternative Names: AVE0897Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genfit; sanofi-aventis
- Developer Sanofi
- Class Antihyperglycaemics
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Europe
- 09 Mar 2009 Phase I development is ongoing in Europe
- 13 Feb 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (unspecified route)